Differences

This shows you the differences between two versions of the page.

--- kyla_hildebrand [2022/04/18 22:19]
liam [Funding]
+++ kyla_hildebrand [2022/04/18 22:26] (current)
liam [Funding]
@@ Line 22: / Line 22: @@
 Hildebrand has received funding from [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[pharmaceutical_companies:CSL Behring]], [[pharmaceutical_companies:MEDA Pharmaceuticals]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Shire Pharma]], [[pharmaceutical_companies:Stallergenes Greer]], [[pharmaceutical_companies:Takeda]], [[pharmaceutical_companies:Teva]], [[pharmaceutical_companies:Aralez]] and
-[[pharmaceutical_companies:Pediapharm]].((Chan, E. S., Abrams, E. M., Hildebrand, K. J., & Watson, W. (2018). //Early introduction of foods to prevent food allergy.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0286-1)) She has also received speakers fees from [[pharmaceutical_companies:Novartis]], and paid travel expenses for [[AllerGen]].((Soller, L., Abrams, E. M., Carr, S., Kapur, S., Rex, G. A., Leo, S., Lidman, P. G., Yeung, J., Vander Leek, T. K., McHenry, M., Wong, T., Cook, V. E., Hildebrand, K. J., Gerstner, T. V., Mak, R., Lee, N. J., Cameron, S. B., & Chan, E. S. (2019). //First real-world safety analysis of preschool peanut oral immunotherapy.// The Journal of Allergy and Clinical Immunology: In Practice, 7(8), 2759-2767.e5. https://doi.org/10.1016/j.jaip.2019.04.010))
+[[pharmaceutical_companies:Pediapharm]] as recently as 2018.((Quirt, J., Hildebrand, K. J., Mazza, J., Noya, F., & Kim, H. (2018). //Asthma.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0279-0)) ((Chan, E. S., Abrams, E. M., Hildebrand, K. J., & Watson, W. (2018). //Early introduction of foods to prevent food allergy.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0286-1)) She has also received speakers fees from [[pharmaceutical_companies:Novartis]], and paid travel expenses for [[AllerGen]].((Soller, L., Abrams, E. M., Carr, S., Kapur, S., Rex, G. A., Leo, S., Lidman, P. G., Yeung, J., Vander Leek, T. K., McHenry, M., Wong, T., Cook, V. E., Hildebrand, K. J., Gerstner, T. V., Mak, R., Lee, N. J., Cameron, S. B., & Chan, E. S. (2019). //First real-world safety analysis of preschool peanut oral immunotherapy.// The Journal of Allergy and Clinical Immunology: In Practice, 7(8), 2759-2767.e5. https://doi.org/10.1016/j.jaip.2019.04.010))
 She has also served as a consultant for [[Food Allergy Canada]], and has received honoraria from [[Health Canada]]. She received a research grant from the [[Canadian Allergy, Asthma, and Immunology Foundation]].((Waserman, S., Cruickshank, H., Hildebrand, K. J., Mack, D., Bantock, L., Bingemann, T., Chu, D. K., Cuello-Garcia, C., Ebisawa, M., Fahmy, D., Fleischer, D. M., Galloway, L., Gartrell, G., Greenhawt, M., Hamilton, N., Hourihane, J., Langlois, M., Loh, R., Muraro, A., & Rosenfield, L. (2021). //Prevention and management of allergic reactions to food in child care centers and schools: Practice guidelines.// Journal of Allergy and Clinical Immunology, 147(5), 1561–1578. https://doi.org/10.1016/j.jaci.2021.01.034))